0.0001USD0.00%Mkt Cap: 4262 USDP/E: —Last update: 2026-05-25
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative coliti…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap4.26K USD
Enterprise Value-16.78M USD
Revenue (TTM)1.10M USD
Gross Profit-66.70M USD
Net Income (TTM)-90.29M USD
Revenue/Share0.0260 USD
Last Price0.0001 USD
Fiscal Year EndDec 2021
MR QuarterDec 2021
Employees76
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.00
PEG—
EV/EBITDA0.20
EV/Revenue-15.20
P/S0.00
P/B0.00
EPS (TTM)-2.16
EPS (Forward)-0.85
52W Range
0.00000% of range0.1900
52W High0.1900 USD
52W Low0.0000 USD
Profitability
Gross Margin0.00%
Oper. Margin-3974.39%
EBITDA Margin0.00%
Profit Margin-8178.26%
ROE-851.21%
ROA-180.08%
Growth
Revenue Growth102.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.09M USD
CapEx (TTM)1.13M USD
FCF Margin-4168.84%
FCF Yield-1079868.61%
Net Debt-16.78M USD
Net Debt/EBITDA0.20
Balance Sheet
Debt/Equity2.05
Current Ratio1.43
Quick Ratio1.33
Book Value/Sh0.2490 USD
Cash/Share0.9030 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.42.62M
Float42.45M
Insiders0.00%
Institutions0.06%
Short Interest
Short Ratio29.3d
Short % Float14.19%
Short % Out.5.49%
Shares Short2.34M
Short (prev mo.)2.16M
Technical
SMA 500.0001 (-9.1%)
SMA 2000.0004 (-74.3%)
Beta38.51
S&P 52W Chg28.31%
Avg Vol (30d)992
Avg Vol (10d)1.34K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—